Inc said on Tuesday that its experimental messenger RNA vaccine for respiratory syncytial virus was 83.7% effective in a late-stage trial at preventing at least two symptoms, such as cough and fever, in adults aged 60 and older.
Pfizer and GSK filed applications for U.S. regulatory approval late last year. Pfizer’s RSV vaccine was found to be 66.7% effective against two or more symptoms in late-stage trials. On the other hand, Sanofi and partner AstraZeneca Plc’s antibody treatment nirsevimab has gained the European Commission’s marketing authorization for the prevention of RSV in newborns and infants. It is currently under review by the U.S. Food and Drug Administration.
“It’s very exciting to see progress in RSV vaccines in older adults, and I think both of those vaccines have shown pretty remarkable results as well,“ Hoge said. “We really think we’re in that top class - 84% is a terrific efficacy number.”
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: staronline - 🏆 4. / 75 Read more »
Source: staronline - 🏆 4. / 75 Read more »